Facebook
Instagram
Linkedin
Pinterest
Twitter
Youtube
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Tag: DBV Technologies
DBV Technologies Submits Biologics License Application to FDA for Viaskin Peanut...
News Wire ~ 3rd Party Press Release
-
2019/08/08
This submission addresses the additional data needed on manufacturing procedures and quality controls which were communicated by the FDA in December.
Fare Responds to Final ICER Review of Breakthrough Peanut Allergy Therapies
News Wire ~ 3rd Party Press Release
-
2019/07/11
FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.
Asthma and Allergy Foundation of America Responds to Premature ICER Review...
Dave Bloom
-
2019/07/11
The AAFA addresses concerns regarding the Final Evidence Report released by the ICER.
ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not...
News Wire ~ 3rd Party Press Release
-
2019/07/11
The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).
Asthma and Allergy Foundation of America Elevates Patient Voice in ICER...
News Wire ~ 3rd Party Press Release
-
2019/06/14
Affirms Burden of Food Allergies on Families, Patients, and Caregivers.
Joint Statement on Peanut Allergy Therapy Review
News Wire ~ 3rd Party Press Release
-
2019/06/13
Organizations representing patients and allergists urge ICER to adopt a more patient-driven approach to assessing immunotherapies for peanut allergy.
DBV to Resubmit Application to FDA for Viaskin Peanut Approval in...
News Wire ~ 3rd Party Press Release
-
2019/02/14
Company allays concerns that BLA would not be resubmitted.
DBV Withdraws FDA Application for Viaskin Peanut with Plan to Resubmit
Dave Bloom
-
2018/12/21
The company believes the additional information needed to support this filing is available without further clinical studies.
DBV Applies for FDA License to Sell Viaskin Peanut Patch Therapy
News Wire ~ 3rd Party Press Release
-
2018/10/23
"This submission represents a significant step forward for those families living with peanut allergy."
Viaskin Peanut Completes Phase III Part A Study of Toddlers With...
News Wire ~ 3rd Party Press Release
-
2018/09/12
Part B expected to commence in 2018Q4 with Viaskin Peanut 250 µg.
1
2
3
4
5
Page 3 of 5